You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 28, 2024

Upjohn Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Upjohn
International Patents:33
US Patents:3
Tradenames:12
Ingredients:9
NDAs:13

Drugs and US Patents for Upjohn

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn LYRICA pregabalin CAPSULE;ORAL 021446-006 Dec 30, 2004 AB RX Yes No ⤷  Sign Up ⤷  Sign Up
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 AB RX Yes No ⤷  Sign Up ⤷  Sign Up
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-003 Aug 29, 2002 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Upjohn EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-001 Oct 20, 1997 AB RX Yes No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Upjohn

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn DETROL tolterodine tartrate TABLET;ORAL 020771-001 Mar 25, 1998 5,559,269*PED ⤷  Sign Up
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-004 Dec 15, 2006 5,563,165*PED ⤷  Sign Up
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-002 Dec 31, 1998 5,972,986*PED ⤷  Sign Up
Upjohn EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997 6,419,958*PED ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for UPJOHN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe 2018-01-29
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe 2018-01-29
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 2006-09-27
➤ Subscribe Extended-release Capsules 2 mg and 4 mg ➤ Subscribe 2007-07-30
➤ Subscribe Capsules 50 mg ➤ Subscribe 2008-03-21
➤ Subscribe Oral Solution 20 mg/mL ➤ Subscribe 2010-05-19
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe 2018-02-02
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe 2018-02-02
➤ Subscribe Tablets 20 mg and 40 mg ➤ Subscribe 2010-03-29
➤ Subscribe Extended-release Tablets 37.5 mg, 75 mg and 150 mg ➤ Subscribe 2007-05-03
➤ Subscribe Capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg ➤ Subscribe 2008-12-30

Supplementary Protection Certificates for Upjohn Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0364417 61/1997 Austria ⤷  Sign Up PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718
0247633 62/1997 Austria ⤷  Sign Up PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0641330 2004C/022 Belgium ⤷  Sign Up PRODUCT NAME: PREGABALIN; REGISTRATION NO/DATE: EU/1/04/279/001 20040708
0934061 PA2004017,C0934061 Lithuania ⤷  Sign Up PRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RUGSTIS); REGISTRATION NO/DATE: EU/1/04/279/001-025 20040725
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.